NCT05502549View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia

PHASE1CompletedINTERVENTIONAL
Enrollment

56

Participants

Timeline

Start Date

November 29, 2022

Primary Completion Date

November 9, 2023

Study Completion Date

December 15, 2023

Conditions
Healthy Volunteers
Interventions
DRUG

CB03-154

CB03-154 tablet once daily.

DRUG

Placebo

Placebo tablet once daily.

Trial Locations (1)

3004

Nucleus Network Pty Limited, Melbourne

All Listed Sponsors
lead

Shanghai Zhimeng Biopharma, Inc.

INDUSTRY